{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:50:32Z","timestamp":1778759432882,"version":"3.51.4"},"reference-count":52,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T00:00:00Z","timestamp":1515715200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013885","name":"Ministry of Health Malaysia","doi-asserted-by":"crossref","award":["JPP 12-046 (NMRR-13-898-17054)"],"award-info":[{"award-number":["JPP 12-046 (NMRR-13-898-17054)"]}],"id":[{"id":"10.13039\/501100013885","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003200","name":"Kementerian Sains, Teknologi dan Inovasi","doi-asserted-by":"publisher","award":["eScience grants (02-02-SF0033; 02-02-09-SF0036)"],"award-info":[{"award-number":["eScience grants (02-02-SF0033; 02-02-09-SF0036)"]}],"id":[{"id":"10.13039\/501100003200","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0191295","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T19:03:18Z","timestamp":1515783798000},"page":"e0191295","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["Ternary copper(II) complex: NCI60 screening, toxicity studies, and evaluation of efficacy in xenograft models of nasopharyngeal carcinoma"],"prefix":"10.1371","volume":"13","author":[{"given":"Munirah","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shazlan-Noor","family":"Suhaimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tai-Lin","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norazlin","family":"Abdul Aziz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noor-Kaslina","family":"Mohd Kornain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. S.","family":"Samiulla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwok-Wai","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chew-Hee","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8268-5271","authenticated-orcid":true,"given":"Alan Soo-Beng","family":"Khoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2018,1,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ica.2016.01.006","article-title":"Current and future potential of metallo drugs: Revisiting DNA-binding of metal containing molecules and their diverse mechanism of action","volume":"444","author":"M Zaki","year":"2016","journal-title":"Inorg Chim Acta"},{"issue":"8","key":"ref2","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1039\/C5DT03919C","article-title":"Metal-based drugs that break the rules","volume":"45","author":"CS Allardyce","year":"2016","journal-title":"Dalton Trans"},{"issue":"35","key":"ref3","doi-asserted-by":"crossref","first-page":"8113","DOI":"10.1039\/c0dt00292e","article-title":"The status of platinum anticancer drugs in the clinic and in clinical trials","volume":"39","author":"NJ Wheate","year":"2010","journal-title":"Dalton Trans"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.taap.2013.10.031","article-title":"Pre-treatment with cardamonin protects against cisplatin-induced nephrotoxicity in rats: impact on NOX-1, inflammation and apoptosis","volume":"274","author":"RN El-Naga","year":"2014","journal-title":"Toxicol Appl Pharmacol"},{"issue":"4","key":"ref5","first-page":"1972","article-title":"Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA","volume":"46","author":"RJ Knox","year":"1986","journal-title":"Cancer Res"},{"issue":"43","key":"ref6","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.1039\/b706075k","article-title":"Developing new metal-based therapeutics: challenges and opportunities","volume":"21","author":"TW Hambley","year":"2007","journal-title":"Dalton Trans"},{"issue":"27","key":"ref7","doi-asserted-by":"crossref","first-page":"8226","DOI":"10.1039\/c2dt30075c","article-title":"Targeted therapy vs. DNA-adduct formation-guided design: thoughts about the future of metal-based anticancer drugs","volume":"41","author":"G Sava","year":"2012","journal-title":"Dalton Trans"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ccr.2014.08.002","article-title":"Noble metals in medicine: Latest advances","volume":"284","author":"S Medici","year":"2015","journal-title":"Coord Chem Rev"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1021\/cr400135x","article-title":"Advances in Copper Complexes as Anticancer Agents","volume":"114","author":"C Santini","year":"2014","journal-title":"Chem Rev"},{"issue":"10","key":"ref10","doi-asserted-by":"crossref","first-page":"15584","DOI":"10.3390\/molecules191015584","article-title":"Cellular transport mechanisms of cytotoxic metallodrugs: an overview beyond cisplatin","volume":"19","author":"S Spreckelmeyer","year":"2014","journal-title":"Molecules"},{"issue":"11","key":"ref11","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1039\/C5MT00163C","article-title":"Homoleptic phosphino copper(I) complexes with in vitro and in vivo dual cytotoxic and anti-angiogenic activity","volume":"7","author":"V Gandin","year":"2015","journal-title":"Metallomics"},{"issue":"11","key":"ref12","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1039\/C5MT00149H","article-title":"Targeting copper in cancer therapy: &apos;Copper That Cancer&apos;","volume":"7","author":"D Denoyer","year":"2015","journal-title":"Metallomics"},{"issue":"13","key":"ref13","doi-asserted-by":"crossref","first-page":"5226","DOI":"10.1021\/acs.jmedchem.5b00651","article-title":"Antiangiogenic activity of mononuclear copper(II) polypyridyl complexes for the treatment of cancers","volume":"58","author":"P Nagababu","year":"2015","journal-title":"J Med Chem"},{"issue":"7","key":"ref14","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1039\/C5MT00027K","article-title":"Synthesis and antitumor mechanisms of a copper(II) complex of anthracene-9-imidazoline hydrazone (9-AIH)","volume":"7","author":"QP Qin","year":"2015","journal-title":"Metallomics"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1039\/C5RA22141B","article-title":"Copper(II) quinolinonato-7-carboxamido complexes as potent antitumor agents with broad spectra and selective effects","volume":"6","author":"R K\u0159ikavov\u00e1","year":"2016","journal-title":"RSC Adv"},{"issue":"11","key":"ref16","doi-asserted-by":"crossref","first-page":"5438","DOI":"10.1016\/j.ejmech.2010.09.004","article-title":"In vivo and in vitro evaluation of highly specific thiolate carrier group copper(II) and zinc(II) complexes on Ehrlich ascites carcinoma tumor model","volume":"45","author":"N Raman","year":"2010","journal-title":"Eur J Med Chem"},{"issue":"3","key":"ref17","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1021\/jm300938r","article-title":"In vitro and in vivo anticancer activity of copper bis(thiosemicarbazone) complexes","volume":"56","author":"D Palanimuthu","year":"2013","journal-title":"J Med Chem"},{"issue":"8","key":"ref18","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1039\/C4MT00035H","article-title":"A comprehensive biological insight of trinuclear copper(II)-tin(IV) chemotherapeutic anticancer drug entity: in vitro cytotoxicity and in vivo systemic toxicity studies","volume":"6","author":"Y Zaidi","year":"2014","journal-title":"Metallomics"},{"issue":"1","key":"ref19","first-page":"85","article-title":"Secondary Ligand Effects on the Cytotoxicity of Several Casiope\u00edna\u2019s Group II Compounds","volume":"56","author":"ME Bravo-G\u00f3mez","year":"2012","journal-title":"J Mex Chem Soc"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10863-015-9640-x","article-title":"Antineoplastic copper coordinated complexes (Casiopeinas) uncouple oxidative phosphorylation and induce mitochondrial permeability transition in cardiac mitochondria and cardiomyocytes","volume":"48","author":"C Silva-Platas","year":"2016","journal-title":"J Bioenerg Biomembr"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.canlet.2016.01.040","article-title":"Global trends in incidence and mortality of nasopharyngeal carcinoma","volume":"374","author":"LL Tang","year":"2016","journal-title":"Cancer Lett"},{"issue":"5","key":"ref22","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"J Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"ref23","unstructured":"Azizah AM, Norsaleha IT, Noor Hashimah A, Asmah ZA, Mastulu W. Malaysian National Cancer Registry Report 2007\u20132011. 2016."},{"issue":"Suppl C","key":"ref24","first-page":"59","article-title":"Nasopharyngeal Carcinoma Database","author":"KC Pua","year":"2008","journal-title":"Med J Malaysia"},{"key":"ref25","first-page":"1","article-title":"Nasopharyngeal Carcinoma: Keys for Translational Medicine and Biology (Advances in Experimental Medicine and Biology) 2013 ed","author":"ASB Khoo","year":"2013"},{"issue":"3","key":"ref26","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.semradonc.2012.03.008","article-title":"Current management of nasopharyngeal cancer","volume":"22","author":"AW Lee","year":"2012","journal-title":"Semin Radiat Oncol"},{"key":"ref27","article-title":"Clinical Insights: Nasopharyngeal Carcinoma\u2013Management Strategies","author":"SS Yom","year":"2014"},{"issue":"4","key":"ref28","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1039\/C3MT00276D","article-title":"Selective anticancer copper(II)-mixed ligand complexes: targeting of ROS and proteasomes","volume":"6","author":"CH Ng","year":"2014","journal-title":"Metallomics"},{"key":"ref29","unstructured":"Ng CH, Kong SM, Khoo AS, Ahmad M, inventors. Copper(II)-Mixed Ligand Complexes with Anticancer Properties. Malaysia patent MY-157886-A. 2016."},{"issue":"1","key":"ref30","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1021\/acschembio.5b00513","article-title":"[Cu(o-phthalate)(phenanthroline)] Exhibits Unique Superoxide-Mediated NCI-60 Chemotherapeutic Action through Genomic DNA Damage and Mitochondrial Dysfunction","volume":"11","author":"C Slator","year":"2016","journal-title":"ACS Chem Biol"},{"issue":"10","key":"ref31","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"C Holohan","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"ref32","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1166\/jbn.2009.1021","article-title":"Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia","volume":"5","author":"P Ma","year":"2009","journal-title":"J Biomed Nanotechnol"},{"issue":"6","key":"ref33","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1021\/cb400070a","article-title":"Organometallic Iridium(III) anticancer complexes with new mechanisms of action: NCI-60 screening, mitochondrial targeting, and apoptosis","volume":"8","author":"JM Hearn","year":"2013","journal-title":"ACS Chem Biol"},{"issue":"1","key":"ref34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1039\/C2TX20051A","article-title":"In vitro models for liver toxicity testing","volume":"2","author":"VY Soldatow","year":"2013","journal-title":"Toxicol Res (Camb)"},{"issue":"6","key":"ref35","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/BF02615992","article-title":"Primary monolayer cultures of adult rat liver parenchymal cells suitable for study of the regulation of enzyme synthesis","volume":"9","author":"RJ Bonney","year":"1974","journal-title":"In Vitro"},{"issue":"96","key":"ref36","doi-asserted-by":"crossref","first-page":"54026","DOI":"10.1039\/C4RA09160D","article-title":"Inhibitory effects of dioscin on cytochrome P450 enzymes","volume":"4","author":"X Tao","year":"2014","journal-title":"RSC Adv"},{"issue":"8","key":"ref37","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(04)01528-1","article-title":"Drug interactions in oncology","volume":"5","author":"JH Beijnen","year":"2004","journal-title":"Lancet Oncol"},{"issue":"4","key":"ref38","doi-asserted-by":"crossref","first-page":"352","DOI":"10.2133\/dmpk.DMPK-13-SH-138","article-title":"Quinine compared to 4beta-hydroxycholesterol and midazolam as markers for CYP3A induction by rifampicin","volume":"29","author":"L Bjorkhem-Bergman","year":"2014","journal-title":"Drug Metab Pharmacokinet"},{"issue":"10","key":"ref39","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S0006-2952(00)00454-8","article-title":"Selective induction of cytochrome P450 3A1 by dexamethasone in cultured rat hepatocytes: Analysis with a novel reverse transcriptase\u2013polymerase chain reaction assay","volume":"60","author":"Hoen PA Chr.\u2019t","year":"2000","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"ref40","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.bbrc.2009.11.021","article-title":"Persistent induction of cytochrome P450 (CYP)1A enzymes by 3-methylcholanthrene in vivo in mice is mediated by sustained transcriptional activation of the corresponding promoters","volume":"390","author":"W Jiang","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"ref41","unstructured":"U.S. Department of Health and Human Services, FDA, Center for Drug Evaluation and Research (CDER). Guidance for industry, drug interaction studies\u2014study design, data analysis, implications for dosing, and labeling recommendations. 2012."},{"issue":"3","key":"ref42","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0009-2797(01)00162-4","article-title":"Species comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog","volume":"134","author":"C Lu","year":"2001","journal-title":"Chem Biol Interact"},{"key":"ref43","unstructured":"Acute Toxicity Determination. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/dtp.cancer.gov\/organization\/btb\/acute_toxicity.htm\" xlink:type=\"simple\">https:\/\/dtp.cancer.gov\/organization\/btb\/acute_toxicity.htm<\/ext-link>."},{"issue":"7","key":"ref44","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/bjc.2014.85","article-title":"Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models","volume":"110","author":"S Cao","year":"2014","journal-title":"Br J Cancer"},{"issue":"1","key":"ref45","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/(SICI)1097-0215(19990924)83:1<121::AID-IJC21>3.0.CO;2-F","article-title":"Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus","volume":"83","author":"ST Cheung","year":"1999","journal-title":"Int J Cancer"},{"issue":"2","key":"ref46","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/ijc.2910260202","article-title":"Establishment of a cell line (NPC\/HK1) from a differentiated squamous carcinoma of the nasopharynx","volume":"26","author":"DP Huang","year":"1980","journal-title":"Int J Cancer"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jinorgbio.2016.02.033","article-title":"Synthesis, characterization, and antitumor activity of three ternary dinuclear copper (II) complexes with a reduced Schiff base ligand and diimine coligands in vitro and in vivo","volume":"159","author":"L Jia","year":"2016","journal-title":"J Inorg Biochem"},{"issue":"36","key":"ref48","doi-asserted-by":"crossref","first-page":"29963","DOI":"10.1039\/C6RA02571D","article-title":"Novel mononuclear ruthenium(II) complexes as potent and low-toxicity antitumour agents: synthesis, characterization, biological evaluation and mechanism of action","volume":"6","author":"P Hu","year":"2016","journal-title":"RSC Adv"},{"issue":"1","key":"ref49","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1101\/gad.232009.113","article-title":"Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53","volume":"28","author":"GL Kelly","year":"2014","journal-title":"Genes Dev"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0091-679X(08)61797-5","article-title":"Preparation of isolated rat liver cells","volume":"13","author":"PO Seglen","year":"1976","journal-title":"Methods Cell Biol"},{"issue":"5","key":"ref51","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1158\/1535-7163.MCT-10-0106","article-title":"Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines","volume":"9","author":"SL Holbeck","year":"2010","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"ref52","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nrc1951","article-title":"The NCI60 human tumour cell line anticancer drug screen","volume":"6","author":"RH Shoemaker","year":"2006","journal-title":"Nat Rev Cancer"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0191295","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T21:30:54Z","timestamp":1589837454000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0191295"}},"subtitle":[],"editor":[{"given":"Salvatore V.","family":"Pizzo","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,1,12]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,1,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0191295","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,12]]}}}